Hipuran- 131I (sodium iodohippurate- 131I injection) is sterile and isotonic solution containing sodium o-iodohippurate in which a portion of molecules contain radioactive iodine - 131I in the molecular structure. The preparation contains carbonate buffer and benzyl alcohol as a microbial preservative. The solution contains:
2 - 20 mg/ml sodium o-iodohippurate
1% benzyl alcohol
3,7 - 74 MBq/ml of I-131
Hipuran- 131I (sodium o-iodohippurate- 131I injection) is a radiopharmaceutical agent applied in diagnosis of kidneys disfunction: functional studies of the kidney, renal blood flow and urinary obstructions, determination of glomerular filtration (GFR) and effective renal plasma flow (ERPF).
Dosage and method of administration
Following intravenous administration the Hipuran- 131I locates in the kidneys where it concentrates and is later excreted. It appears in kidneys very fast, 1 - 3 min. after administration. Plasma disappearance of sodium iodohippurate- 131I is dependent upon plasma flow rate; the effective half-life is short (about 20 min.) under normal conditions. Radiolabelled iodohippurate can be used clinically to estimate renal plasma flow and glomerular filtration rate.
The recommended dose is 0,185 - 1,295 MBq ( 5 - 35 μCi ) / 70 kg.
The side-effects of diagnostic doses were not observed and contraindications are not present.
Organ mGy / MBq
Bladder 0.578 - 1.219
Whole Body 0.005
Characteristics of the product
The preparation of Hipuran- 131I forms a clear and colourless solution of the following parameters:
Radiochemical purity: I- ≤ 2 % I- ≤ 1 % Radioactive concentration 3,7 - 74 MBq/ml Specific activity 0,8 - 8.0 MBq/mg pH 6,0 - 8,0
≤ 2 %
≤ 1 %
3,7 - 74 MBq/ml
0,8 - 8.0 MBq/mg
6,0 - 8,0
2 - 8 0C.